Alfacalcidol has a weaker impact on [[calcium metabolism]]<ref>{{cite journal | last1 = | first1 = | year = 2009 | title = Biological effects of various regimes of 25-hydroxyvitamin D3 (calcidiol) administration on bone mineral metabolism in postmenopausal women | pmc = 2781231| journal = Clin Cases Miner Bone Metab | volume = 6 | issue = 2| pages = 169–173 | pmid=22461169}}</ref> and [[parathyroid hormone]] levels<ref>{{cite journal | last1 = | first1 = | year = 2008 | title = Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial | url = http://www.jptcp.com/cjcp07017_wazny_e36-e43v2-r101690 | journal = Can J Clin Pharmacol | volume = 15 | issue = 1| pages = e36–e43 }}</ref> than [[calcitriol]], however alfacalcidol has significant effects on the [[immune system]], including [[regulatory T cells]].<ref>Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease, Autoimmunity Reviews, August 2010;</ref> It is considered to be a more useful form of [[vitamin D]] supplementation, mostly due to much longer half-life and lower kidney load.<ref>{{cite journal | last1 = | first1 = | date = Mar 2006 | title = Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis | url = | journal = Rheumatol Int. | volume = 26 | issue = 5| pages = 445–53 | doi = 10.1007/s00296-005-0073-4 | pmid = 16283320 }}</ref> It is the most commonly prescribed vitamin D metabolite for patients with [[end stage renal disease]], given that impaired renal function alters the ability to carry out the second [[hydroxylation]] step required for the formation of the physiologically active form of vitamin D, [[1,25-dihydroxyvitamin D3]]. Alfacalcidol is an active vitamin D3 metabolite, and therefore does not require the second [[hydroxylation]] step in the [[kidney]].<ref>{{cite journal | pmid = 11770836 | volume=39 | title=Alfacalcidol in the therapy of renal bone disease. | date=Dec 2001 | journal=Int J Clin Pharmacol Ther | pages=546–50 | doi=10.5414/cpp39546}}</ref>
